Recent Updates
Recently added Catalysts
MIRA Neutral Sentiment

Q2 Quarterly results 2026

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA has released its Q2 quarterly results for 2026, providing an overview of its financial performance. The report includes details on income statements, balance sheets, and cash flow. The company also highlights its governance and investor relations information. Further details can be found in the provided SEC filings.
Price reaction · baseline $0.7387 (2026-08-12 close) · hit after-hours · clean, no other MIRA news in the window
day 0 close
+1.5%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+26%
120-day peak, hindsight
Typical move
2.7%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Ketamir-2
Phase 1 · Healthy Adult Participants

Full Press Release Details

Press Releases

• Overview
• News & Events Press Releases IR Calendar Presentations Email Alerts
• Company Info Overview Contacts FAQ
• Financial Info Overview Financial Results Income Statement Balance Sheet Cash Flow
• Stock Data Quotes Charts Historic Data Analyst Coverage
• SEC Filings Overview All SEC Filings Annual Reports Quarterly Results Section 16 Filings
• Governance Overview Board Committees Governance Documents
• Press Releases
• IR Calendar
• Presentations
• Email Alerts
• Overview
• Contacts
• FAQ
• Overview
• Financial Results
• Income Statement
• Balance Sheet
• Cash Flow
• Quotes
• Charts
• Historic Data
• Analyst Coverage
• Overview
• All SEC Filings
• Annual Reports
• Quarterly Results
• Section 16 Filings
• Overview
• Board Committees
• Governance Documents

Q2 Quarterly results 2026

General form for quarterly reports under Section 13 or 15(d) (PDF) General form for quarterly reports under Section 13 or 15(d) (DOCX)
ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare Q2 2026 financial results income statement balance sheet
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$8M liquidity · $0M/mo burn
~19 mo
Low dilution risk
Lead asset
Ketamir-2Phase 1
Healthy Adult Participants →

Catalyst track record

+26%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →